A development stage pharmaceutical company engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases.


Updates from The Motley Fool

Latest updates on Galectin Therapeutics from Fool.com.


Stock Performance

View Interactive GALT Charts
Sponsored by

Key Data Points

Primary metrics and data points about Galectin Therapeutics.
Current Price: $0.87
Prev Close: $0.87
Open: $0.87
Bid: $0.87
Ask: $0.93
Day's Range: $0.87 - $0.89
52wk Range: $0.49 - $3.05
Volume: 98,878
Avg Vol 302,753
Market Cap: $21M
P/E (ttm): -1.05
EPS (ttm): ($0.83)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Galectin Therapeutics.
CAPS Rating 2 out of 5
 
60 Outperform
40 Underperform
CAPS All Stars
 
12 Outperform
25 Underperform

How do you think Galectin Therapeutics will perform against the market?



You pick for Galectin Therapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


Business Summary

Industry, sector and description for Galectin Therapeutics.

A development stage pharmaceutical company engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers